Home

  Third International Conference on Financing for Development

Third International Conference on Financing for Development Third International Conference on Financing for Development Invest Ahead - For People and Planet #FFD3 #Action2015 Home Overview Programme Initiatives Documents News & Media Blog A £735m capital increase to CDC Group to invest in businesses to create jobs in the world’s poorest places Type Government announcement Country United Kingdom Government type Central government Scope Global Themes International public finance Description The UK will make an injection of additional capital into CDC, which will be used to invest in businesses in Africa and South Asia to support job creation, crowd in additional private investment, and demonstrate that responsible investing in difficult markets can be financially viable. Partners CDC Targets The UK will make an injection of additional capital into CDC. £735m will be disbursed over 3 years. Indicators The UK will make an injection of additional capital into CDC. £735m will be disbursed over 3 years.

Score: 989120.9 - https://www.un.org/esa/ffd/ffd...tal-increase-to-cdc-group.html

  A Cooperation that C

Studies show that the most vulnerable adolescents who inject drugs use non sterile injecting equipment, thus being directly exposed to HIV and other infections.1 Meanwhile, only a third of young people in Moldova, 15-24 years of age, has comprehensive knowledge about HIV transmission and prevention.2 Even though in Moldova there are many youth friendly health centres (YFHC) working with young people, they are mostly inaccessible to the MARA and EVA groups. (...) Ministry of Health of the Republic of Moldova *Most-at-risk adolescents (MARA): Injecting drug users who use non sterile injecting equipment; males who have unprotected anal sex with males; sex workers. **Especially vulnerable adolescents (EVA): Adolescent females and males who are/have: children/parents who inject drugs; friends/peers who inject drugs/have unsafe sex; living in institutional care, especially juvenile detention; living/working on the street; migrant populations; minority or socially excluded groups. 1 Assessment of the situation of Youth in the Republic of Moldova, 2009 2 Multiple Indicator Cluster Survey, 2012 Capacity building • 77 professionals from NGOs and Youth Friendly Health Centres have strengthened their capaci- ties in provision of HTC services for most-at-risk and especially vulnerable adolescents; • Ukrainian representatives from NGOs, public sector, and UNICEF participated in a study visit to Moldova and exchanged experience with Moldovan professionals; • Specialists from Moldovan NGOs (“TDV”, Balti and “Healthy Life”, Tiraspol) attended a professional training course in Odessa; • Moldovan representatives partici- pated in the Regional Working Meeting on Scaling up HIV Testing and Counselling in Azerbaijan in November 2012 and learned how to improve access of the most-at- risk and vulnerable adolescents to HTC and HIV prevention, protec- tion, care and support services.

Score: 988406.1 - https://www.unicef.org/moldova...s/2018-09/MARA%20projectEN.pdf

  WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta

WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta Global Regions WHO Regional websites Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific When autocomplete results are available use up and down arrows to review and enter to select. Select language Select language English العربية 中文 Français Русский Español Home Health Topics All topics » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Resources » Fact sheets Facts in pictures Multimedia Publications Questions & answers Tools and toolkits Popular » Coronavirus disease (COVID-19) Ebola virus disease Air pollution Hepatitis Top 10 causes of death World Health Assembly » Countries All countries » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Regions » Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific WHO in countries » Statistics Cooperation strategies Yemen crisis » Sadeq Al Wesabi Hasan An internally displaced family in a camp in Hudaydah © Credits   Newsroom All news » News releases Statements Campaigns Commentaries Events Feature stories Speeches Spotlights Newsletters Photo library Media distribution list Headlines » Timeline: WHO's COVID-19 response »   Emergencies Focus on » COVID-19 pandemic Ebola virus disease outbreak DRC 2021 Syria crisis Crisis in Northern Ethiopia Afghanistan Crisis Latest » Disease Outbreak News Travel advice Situation reports Weekly Epidemiological Record WHO in emergencies » Surveillance Research Funding Partners Operations Independent Oversight and Advisory Committee Health Emergency Dashboard » WHO © Credits Data Data at WHO » Global Health Estimates Health SDGs Mortality Triple billion targets Data collections Dashboards » COVID-19 Dashboard Triple Billion Dashboard Health Equity monitor Mortality Highlights » GHO SCORE Insights and visualizations Data collection tools Reports World Health Statistics 2021 » WHO © Credits About WHO About WHO » People Teams Structure Partnerships Collaborating Centres Networks, committees and advisory groups Transformation Our Work » General Programme of Work WHO Academy Activities Initiatives Funding » Assessed contributions Flexible funding WHO Foundation Accountability » Audit Budget Financial statements Programme Budget Portal Results Report Governance » World Health Assembly Executive Board Election of Director-General Governing Bodies website Home / Publications detail / WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta 4 November 2020  |  Guideline Download (686.5 kB) Overview In 2019, the Executive Guideline Steering Group (GSG) for the World Health Organization (WHO) maternal and perinatal health recommendations prioritized updating of the existing WHO recommendation: Umbilical vein injection of oxytocin for the treatment of retained placenta, in response to the availability of new evidence. The recommendation in this document thus supersedes the previous WHO recommendations on “intraumbilical vein injection of oxytocin for treatment of retained placenta” as published in the 2012 guideline, WHO recommendations for the prevention and treatment of postpartum haemorrhage .

Score: 986989.3 - https://www.who.int/publicatio...-detail-redirect/9789240013940

  WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta

WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta Global Regions WHO Regional websites Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific When autocomplete results are available use up and down arrows to review and enter to select. Select language Select language English العربية 中文 Français Русский Español Português Home Health Topics All topics » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Resources » Fact sheets Facts in pictures Multimedia Publications Questions & answers Tools and toolkits Popular » Coronavirus disease (COVID-19) Ebola virus disease Air pollution Hepatitis Top 10 causes of death World Health Assembly » Countries All countries » A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Regions » Africa Americas South-East Asia Europe Eastern Mediterranean Western Pacific WHO in countries » Statistics Cooperation strategies Yemen crisis » Sadeq Al Wesabi Hasan An internally displaced family in a camp in Hudaydah © Credits   Newsroom All news » News releases Statements Campaigns Commentaries Events Feature stories Speeches Spotlights Newsletters Photo library Media distribution list Headlines » Timeline: WHO's COVID-19 response »   Emergencies Focus on » COVID-19 pandemic Ebola virus disease outbreak DRC 2021 Syria crisis Crisis in Northern Ethiopia Afghanistan Crisis Latest » Disease Outbreak News Travel advice Situation reports Weekly Epidemiological Record WHO in emergencies » Surveillance Research Funding Partners Operations Independent Oversight and Advisory Committee Health Emergency Dashboard » WHO © Credits Data Data at WHO » Global Health Estimates Health SDGs Mortality Triple billion targets Data collections Dashboards » COVID-19 Dashboard Triple Billion Dashboard Health Equity monitor Mortality Highlights » GHO SCORE Insights and visualizations Data collection tools Reports World Health Statistics 2021 » WHO © Credits About WHO About WHO » People Teams Structure Partnerships Collaborating Centres Networks, committees and advisory groups Transformation Our Work » General Programme of Work WHO Academy Activities Initiatives Funding » Assessed contributions Flexible funding WHO Foundation Accountability » Audit Budget Financial statements Programme Budget Portal Results Report Governance » World Health Assembly Executive Board Election of Director-General Governing Bodies website Home / Publications / i / item / WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta - Select language - العربية 中文 français русский español português WHO recommendation on umbilical vein injection of oxytocin for the treatment of retained placenta 4 November 2020  |  Guideline Download (686.5 kB) Overview In 2019, the Executive Guideline Steering Group (GSG) for the World Health Organization (WHO) maternal and perinatal health recommendations prioritized updating of the existing WHO recommendation: Umbilical vein injection of oxytocin for the treatment of retained placenta, in response to the availability of new evidence. The recommendation in this document thus supersedes the previous WHO recommendations on “intraumbilical vein injection of oxytocin for treatment of retained placenta” as published in the 2012 guideline, WHO recommendations for the prevention and treatment of postpartum haemorrhage .

Score: 986989.3 - https://www.who.int/publications/i/item/9789240013940

  WHO's Infection prevention & control department

Download Read More 5 April 2022 Injection safety in the context of coronavirus disease (COVID-19) vaccination: Addendum to policy brief,... This policy brief confirms WHO guidance and policy on injection safety in the context of the extraordinary increase in global injections resulting from... Download Read More 5 November 2021 Injection safety in the context of coronavirus disease (COVID-19) vaccination This policy brief synthesizes WHO guidance and policy on injection safety in the context of the extraordinary increase in global injections resulting from...

Score: 986078.5 - https://www.who.int/teams/inte.../infection-prevention-control/

  WHO's Infection prevention & control department

Download Read More 5 April 2022 Injection safety in the context of coronavirus disease (COVID-19) vaccination: Addendum to policy brief,... This policy brief confirms WHO guidance and policy on injection safety in the context of the extraordinary increase in global injections resulting from... Download Read More 5 November 2021 Injection safety in the context of coronavirus disease (COVID-19) vaccination This policy brief synthesizes WHO guidance and policy on injection safety in the context of the extraordinary increase in global injections resulting from...

Score: 986078.5 - https://www.who.int/teams/inte...s/infection-prevention-control

  CountryProfile

Seroprevalence among highly affected populations of injecting drug users has reached as high as 48% in Jakarta, 53% in Denpasar, Bali, and 24% in West Java. (...) The 2002 national estimates indicated that the HIV prevalence ranges from 19% to 34% among injecting drug users and from 2% to 5% among sex workers. (...) HIV transmission in Indonesia was initially related to sexual transmission, but transmission among injecting drug users has increased eight-fold since 1998.

Score: 985773.9 - https://www.who.int/3by5/support/june2005_idn.pdf

  Bliss in the dark | UNICEF

One of them is a 21-year-old boy, a heroin injecting drug user. The woman sitting beside him is his mother. (...) At the age of 17 I tried heroin and I'd been injecting it for four years." He became a regular drug user at the age of 12. (...) A month ago he decided to quit injecting heroin. The latest HIV/Hepatitis B and C tests show that he is clean.

Score: 984340 - https://www.unicef.org/serbia/en/stories/bliss-dark

  Eliminate hepatitis: WHO

This week, WHO has also added a new generic treatment to its list of WHO-prequalified hepatitis C medicines to increase access to therapy, and is promoting prevention through injection safety: a key factor in reducing hepatitis B and C transmission. (...) There is also an urgent need to scale up access to hepatitis B testing. Improving injection safety and infection prevention to reduce new cases of hepatitis B and C Use of contaminated injection equipment in health-care settings accounts for a large number of new HCV and HBV infections worldwide, making injection safety an important strategy.Others include preventing transmission through invasive procedures, such as surgery and dental care; increasing hepatitis B vaccination rates and scaling up harm reduction programmes for people who inject drugs. Today WHO is launching a range of new educational and communication tools to support a campaign entitled "Get the Point-Make smart injection choices" to improve injection safety in order to prevent hepatitis and other bloodborne infections in health-care settings.  

Score: 984340 - https://www.who.int/news/item/...7-2017-eliminate-hepatitis-who

  WHO | Can women who are at high risk of acquiring HIV, safely use hormonal contraception?

The revised recommendation is that progestogen-only injectables (norethisterone enanthate [NET-EN] and depot medroxyprogesterone acetate [DMPA, intramuscular or subcutaneous]) can be used by women at high risk of HIV, because the advantages of these methods generally outweigh the possible, but unproven, increased risk of HIV acquisition. (...) This is now changed to a category 2; meaning women can use progestogen-only injectables but should be advised about concerns that these methods may increase risk of HIV acquisition, about the uncertainty over whether there is a causal relationship, and about how to minimize their risk of acquiring HIV. This revised guidance places greater emphasis on the importance of shared decision making and need for counselling on concerns that progestogen-only injectables may increase the risk of HIV infection.

Score: 982339.55 - https://www.who.int/reproducti...hormonal-contraception-hiv/en/